收费全文 | 92739篇 |
免费 | 5773篇 |
国内免费 | 725篇 |
耳鼻咽喉 | 1075篇 |
儿科学 | 2819篇 |
妇产科学 | 2283篇 |
基础医学 | 12486篇 |
口腔科学 | 2115篇 |
临床医学 | 7494篇 |
内科学 | 20282篇 |
皮肤病学 | 1944篇 |
神经病学 | 8612篇 |
特种医学 | 3635篇 |
外国民族医学 | 23篇 |
外科学 | 13081篇 |
综合类 | 1645篇 |
一般理论 | 47篇 |
预防医学 | 5332篇 |
眼科学 | 1471篇 |
药学 | 7596篇 |
3篇 | |
中国医学 | 519篇 |
肿瘤学 | 6775篇 |
2023年 | 393篇 |
2022年 | 934篇 |
2021年 | 1677篇 |
2020年 | 1104篇 |
2019年 | 1547篇 |
2018年 | 1933篇 |
2017年 | 1481篇 |
2016年 | 1543篇 |
2015年 | 1803篇 |
2014年 | 2372篇 |
2013年 | 3506篇 |
2012年 | 4659篇 |
2011年 | 4840篇 |
2010年 | 3172篇 |
2009年 | 2775篇 |
2008年 | 4297篇 |
2007年 | 4483篇 |
2006年 | 4279篇 |
2005年 | 4090篇 |
2004年 | 4434篇 |
2003年 | 4298篇 |
2002年 | 4353篇 |
2001年 | 3684篇 |
2000年 | 3642篇 |
1999年 | 2940篇 |
1998年 | 1109篇 |
1997年 | 868篇 |
1996年 | 802篇 |
1995年 | 774篇 |
1994年 | 679篇 |
1993年 | 662篇 |
1992年 | 1768篇 |
1991年 | 1744篇 |
1990年 | 1483篇 |
1989年 | 1436篇 |
1988年 | 1316篇 |
1987年 | 1175篇 |
1986年 | 1163篇 |
1985年 | 1029篇 |
1984年 | 764篇 |
1983年 | 692篇 |
1982年 | 444篇 |
1981年 | 381篇 |
1979年 | 565篇 |
1978年 | 418篇 |
1975年 | 428篇 |
1974年 | 479篇 |
1973年 | 461篇 |
1972年 | 421篇 |
1971年 | 392篇 |
To determine frequencies, interlaboratory reproducibility, clinical ratings, and prognostic implications of neural antibodies in a routine laboratory setting in patients with suspected neuropsychiatric autoimmune conditions.
MethodsEarliest available samples from 10,919 patients were tested for a broad panel of neural antibodies. Sera that reacted with leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-2 (CASPR2), or the voltage-gated potassium channel (VGKC) complex were retested for LGI1 and CASPR2 antibodies by another laboratory. Physicians in charge of patients with positive antibody results retrospectively reported on clinical, treatment, and outcome parameters.
ResultsPositive results were obtained for 576 patients (5.3%). Median disease duration was 6 months (interquartile range 0.6–46 months). In most patients, antibodies were detected both in CSF and serum. However, in 16 (28%) patients with N-methyl-d-aspartate receptor (NMDAR) antibodies, this diagnosis could be made only in cerebrospinal fluid (CSF). The two laboratories agreed largely on LGI1 and CASPR2 antibody diagnoses (κ = 0.95). The clinicians (413 responses, 71.7%) rated two-thirds of the antibody-positive patients as autoimmune. Antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), NMDAR (CSF or high serum titer), γ-aminobutyric acid-B receptor (GABABR), and LGI1 had ≥ 90% positive ratings, whereas antibodies against the glycine receptor, VGKC complex, or otherwise unspecified neuropil had ≤ 40% positive ratings. Of the patients with surface antibodies, 64% improved after ≥ 3 months, mostly with ≥ 1 immunotherapy intervention.
ConclusionsThis novel approach starting from routine diagnostics in a dedicated laboratory provides reliable and useful results with therapeutic implications. Counseling should consider clinical presentation, demographic features, and antibody titers of the individual patient.
相似文献Methods: Attributes were defined from a literature search, clinician and patient interviews: shape, dose insertion, dose preparation, dose release, dose confirmation, dose counter and reusability. An online DCE was conducted in respondents with self-reported COPD stage 2–4 recruited through a panel. The study questionnaire included twelve choice scenarios per respondent and questions on patient characteristics, treatment and disease severity. Statistical analyses used a mixed logit regression model with random effects. Utility scores were estimated for four types of inhalers: Inhaler A – soft mist inhaler; Inhaler B – reusable soft mist inhaler; Inhaler C – multi-dose dry powder inhaler; and Inhaler D – single dose dry powder inhaler.
Results: The study was completed by 153 patients (50 females); respondents were 50.4?years old on average; 13 different inhaler devices were reported. The most preferred inhaler is L-shaped, has dose preparation with capsule insertion and a dose counter, and is reusable. Inhaler profiles A and B had the highest utilities (mean of 1.2533 and 0.9578 respectively) compared to inhaler C (0.6315) and D (0.2200).
Conclusions: This study showed statistically significant results that the strongest drivers of preference in French users of inhalation devices for COPD are shape, dose counter and reusability. Convenience-related characteristics are important to patients and should be taken into account by clinicians prescribing these devices. 相似文献